Notice to Comply	Application No. 09/673,716	Applicant(s) PAVLAKIS ET AL.
	Examiner Ulrike Winkler, Ph.D.	Art Unit 1648

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☐ 7. Other:

Applicant Must Provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support
    Technical Assistance...703-287-0200
    To Purchase PatentIn Software.......................703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED

JUN 2 4 2002

TECH CENTER 1600/2900

1600

RAW SEQUENCE LISTING   DATE: 06/06/2002
PATENT APPLICATION: US/09/673,716   TIME: 10:29:42

Input Set : A:\Nih352-1.app
Output Set: N:\CRF3\06062002\I673716.raw

ENTERED

```
 3 <110> APPLICANT: Pavlakis, George N.
 4       Nappi, Filomena
 5       The Government of the United States
 6       as represented by the Secretary of
 7       The Department of Health and Human Services
 9 <120> TITLE OF INVENTION: Novel Post-Transcriptional Regulatory Elements and Uses
10       Thereof
12 <130> FILE REFERENCE: 015280-352100US
14 <140> CURRENT APPLICATION NUMBER: US 09/673,716
15 <141> CURRENT FILING DATE: 2001-02-26
17 <150> PRIOR APPLICATION NUMBER: US 60/086,487
18 <151> PRIOR FILING DATE: 1998-05-22
20 <150> PRIOR APPLICATION NUMBER: WO PCT/US99/11082
21 <151> PRIOR FILING DATE: 1999-05-18
23 <160> NUMBER OF SEQ ID NOS: 6
25 <170> SOFTWARE: PatentIn Ver. 2.0
27 <210> SEQ ID NO: 1
28 <211> LENGTH: 231
29 <212> TYPE: DNA
30 <213> ORGANISM: Artificial Sequence
32 <220> FEATURE:
33 <223> OTHER INFORMATION: Description of Artificial Sequence:core
34       post-transcriptional regulatory element (PRE)
35       designated "fragment B"
37 <400> SEQUENCE: 1
38 gtggggtgcg aggctaagca ctgcacagag gatagcttgc tgttggcatc ctgtggaagg 60
39 cacgtctgat tgcatgaagg ttcagtgtcc tagttccctt cccccaggaa aaacgacacg 120
40 ggagctggcc aagacctctc tgggtgatga gcctaaggga tggttttgtg tagggcccct 180
41 atgcttgcac actggggatc agacctctac cttcacccat gaggcttgct t          231
43 <210> SEQ ID NO: 2
44 <211> LENGTH: 30
45 <212> TYPE: DNA
46 <213> ORGANISM: Artificial Sequence
48 <220> FEATURE:
49 <223> OTHER INFORMATION: Description of Artificial Sequence:illustrative
50       primer oligonucleotide complementary to 3' thirty
51       nucleic acids of SEQ ID NO:1
53 <400> SEQUENCE: 2
54 aagcaagcct catgggtgaa ggtagaggac                                  30
56 <210> SEQ ID NO: 3
57 <211> LENGTH: 30
58 <212> TYPE: DNA
59 <213> ORGANISM: Artificial Sequence
```

```
 61 <220> FEATURE:
 62 <223> OTHER INFORMATION: Description of Artificial Sequence:illustrative
 63       primer oligonucleotide incorporating the 5' thirty
 64       nucleic acids of SEQ ID NO:1
 66 <400> SEQUENCE: 3                                          30
 67 gtggggtgcg aggctaagca ctgcacagag
 69 <210> SEQ ID NO: 4
 70 <211> LENGTH: 391
 71 <212> TYPE: DNA
 72 <213> ORGANISM: Artificial Sequence
 74 <220> FEATURE:
 75 <223> OTHER INFORMATION: Description of Artificial Sequence:"rescuing"
 76       post-transcriptional regulatory element (PRE)
 77       insert designated "PRE7"
 79 <400> SEQUENCE: 4
 80 ctttcgccat ggtagcatag gcttttgctg cagtggaggc gggacaatct cctcagattc 60
 81 ggtttgccgc tctaaaagaa attatgctgc gttatgccgt ggggtgcgag gctaagcact 120
 82 gcacagagga tagcttgctg ttggcatcct gtggaaggca cgtctgattg catgaaggtt 180
 83 cagtgtccta gttcccttcc cccaggaaaa acgacacggg agctggccaa gacctctctg 240
 84 ggtgatgagc ctaagggatg gttttgtgta gggcccctat gcttgcacac tggggatcag 300
 85 acctctacct tcacccatga ggcttgcttg cagcaattaa gatctggcca taggttaatt 360
 86 aacatcctgg cctttgatg cacctgccac a                              391
 88 <210> SEQ ID NO: 5
 89 <211> LENGTH: 226
 90 <212> TYPE: DNA
 91 <213> ORGANISM: Artificial Sequence
 93 <220> FEATURE:
 94 <223> OTHER INFORMATION: Description of Artificial Sequence:functional
 95       fragment named "M4"
 97 <400> SEQUENCE: 5
 98 ccgtggggtg cgaggctaag cactgcacag aggatagctt gctgttggca tcctgtggaa 60
 99 ggcacgtctg attgcatgaa ggttcagtgt cctagttccc ttcccccagg aaaaacgaca 120
100 cgggagctgg ccaagacctc tctgggtgat gagcctaagg gatggttttg tgtagggccc 180
101 ctatgcttgc acactgggga tcagacctct accttcaccc atgagg               226
103 <210> SEQ ID NO: 6
104 <211> LENGTH: 100
105 <212> TYPE: DNA
106 <213> ORGANISM: Artificial Sequence
108 <220> FEATURE:
109 <223> OTHER INFORMATION: Description of Artificial Sequence:PRE sequence
110       having about 83% sequence identity to SEQ ID NO:1
112 <220> FEATURE:
113 <221> NAME/KEY: modified_base
114 <222> LOCATION: (1)..(100)
115 <223> OTHER INFORMATION: n = any nucleotide
117 <400> SEQUENCE: 6
118 aggagttgca aggctaagcn actgcacagg agaggntctg cggnntataa cgactttctc 60
119 ctgggagata agtcatcttg catgaaggtt ctatgntcat                       100
```

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/673,716

DATE: 06/06/2002
TIME: 10:29:43

Input Set : A:\Nih352-1.app
Output Set: N:\CRF3\06062002\I673716.raw

Please Note:
Use of n and/or Xaa have been detected in the Sequence Listing. Please review the
Sequence Listing to ensure that a corresponding explanation is presented in the <220>
to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:6; N Pos. 20,36,44,45,96

6/6/02